{"groups":[{"description":"Patients undergo total body irradiation (TBI) on days -7 to -4 and receive cyclophosphamide IV on days -3 and -2. Alternatively, patients may receive cyclophosphamide on days -7 and -6 and undergo TBI on days -4 to -1.\n\ncyclophosphamide\n\ncyclosporine\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"FG000","title":"Regimen I"},{"description":"Patients receive busulfan IV over 2 hours once on day -8 and then every 6 hours on days -7 to -4. Patients also receive cyclophosphamide IV on days -3 and -2.\n\nbusulfan\n\ncyclophosphamide\n\ncyclosporine\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"FG001","title":"Regimen II"},{"description":"Patients undergo TBI on days -7 to -4 and receive etoposide IV on day -3.\n\ncyclosporine\n\netoposide\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"FG002","title":"Regimen III"},{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -7 to -3 and melphalan IV on day -2.\n\ncyclosporine\n\nfludarabine phosphate\n\nmelphalan\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"FG003","title":"Regimen IV"},{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -4 to -2 and undergo TBI on day 0.\n\ncyclosporine\n\nfludarabine phosphate\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation","id":"FG004","title":"Regimen V"},{"description":"Patients receive busulfan IV over 3 hours and fludarabine phosphate IV over 30 minutes on days -5 to -2.\n\nbusulfan\n\ncyclosporine\n\nfludarabine phosphate\n\nmethotrexate\n\nmycophenolate mofetil\n\nsirolimus\n\ntacrolimus\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation","id":"FG005","title":"Regimen VI"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"130"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"40"},{"groupId":"FG005","numSubjects":"2"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"130"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"40"},{"groupId":"FG005","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"Among the 260 enrolled patients, who consented to the study, 5 patients were not eligible."}